keyword
MENU ▼
Read by QxMD icon Read
search

Pazopanib renal

keyword
https://www.readbyqxmd.com/read/28077238/patterns-of-care-and-clinical-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-results-from-a-tertiary-cancer-center-in-india
#1
Anant Ramaswamy, Amit Joshi, Vanita Noronha, Vijay M Patil, Rushabh Kothari, Arvind Sahu, Ram Abhinav Kannan, Nilesh Sable, Palak Popat, Santosh Menon, Kumar Prabhash
INTRODUCTION: The current treatment of metastatic renal cell carcinoma (mRCC) revolves around targeted agents, which have resulted in a median overall survival of 22 to 26 months in registration trials. However, the outcomes in a non-trial, real-world Indian population have not yet been evaluated. MATERIALS AND METHODS: The present study was a part of a prospective Clinical Trials Registry-India-registered study, the Kidney Cancer Registry, a prospectively maintained kidney cancer registry...
October 19, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27986807/effects-of-4-multitargeted-receptor-tyrosine-kinase-inhibitors-on-regional-hemodynamics-in-conscious-freely-moving-rats
#2
Joanne J Carter, Laurice V Fretwell, Jeanette Woolard
VEGF inhibitors, including receptor tyrosine kinase inhibitors, are used as adjunct therapies in a number of cancer treatments. An emerging issue with these drugs is that most cause hypertension. To gain insight into the physiological mechanisms involved, we evaluated their regional hemodynamic effects in conscious rats. Male Sprague Dawley rats (350-450 g) were chronically implanted with pulsed Doppler flow probes (renal and mesenteric arteries, and the descending abdominal aorta) and catheters (jugular vein, peritoneal cavity, and distal abdominal aorta)...
December 16, 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27972548/cost-minimization-analysis-of-using-pazopanib-in-first-line-treatment-in-patients-with-metastatic-renal-cell-carcinoma
#3
M E Romero Prada, S Celis, P A Alfonso Quiñones, G Acero
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972535/cost-effectiveness-of-sunitinib-versus-pazopanib-and-best-supportive-care-for-the-treatment-of-metastatic-renal-cell-carcinoma-in-chile
#4
C Vargas, M A Espinoza, A Giglio
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972530/cost-effectiveness-analysis-of-using-everolimus-or-axitinib-in-patients-with-metastatic-renal-cell-carcinoma-who-have-failed-to-use-of-pazopanib-or-sunitinib-in-first-line-treatment
#5
M E Romero Prada, L M Huerfano, N C Roa Cardenas
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972516/cost-effectiveness-of-pazopanib-compared-to-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#6
A Fouad, A Atia, Y Omar, M Shawky, M Sakr
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972451/cost-comparison-in-the-management-of-the-renal-cell-carcinoma-with-in-spain-pazopanib-vs-sunitinib
#7
E Padron, L Flores
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972444/budget-impact-analysis-of-using-pazopanib-everolimus-in-first-and-second-line-of-treatment-in-patients-with-metastatic-renal-cell-carcinoma
#8
M E Romero Prada, S Celis, G Acero, L M Huerfano
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27928431/corrigendum-to-pazopanib-in-the-treatment-of-advanced-renal-cell-carcinoma-by-david-cella-and-jennifer-l-beaumont-therapeutic-advances-in-urology-2016-vol-8-1-61-69-doi-10-1177-1756287215614236
#9
(no author information available yet)
[This corrects the article DOI: 10.1177/1756287215614236.].
August 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27924140/corrigendum-pazopanib-in-metastatic-renal-cancer-a-real-world-experience-at-national-cancer-institute-fondazione-g-pascale
#10
Sabrina C Cecere, Sabrina Rossetti, Carla Cavaliere, Chiara Della Pepa, Marilena Di Napoli, Anna Crispo, Gelsomina Iovane, Raffaele Piscitelli, Domenico Sorrentino, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdonà, Massimiliano Berretta, Sandro Pignata, Gaetano Facchini, Carmine D'Aniello
[This corrects the article on p. 287 in vol. 7, PMID: 27630568.].
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27923360/tumour-response-in-metastatic-renal-cell-carcinoma-treated-with-tyrosine-kinase-inhibitors-assessment-of-intra-tumour-heterogeneity
#11
EDITORIAL
Viktoria Stühler, Jens Bedke
Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC), representing the genetic complexity of a tumour with multiple metastatic sites. The present commentary discusses the observed phenomena of phenotypic intra-tumour heterogeneity in mRCC patients treated with the tyrosine kinase inhibitors sunitinib or pazopanib. Here, drug response can be different on the level of each evaluated metastasis in the individual patient. This questions the currently used radiologic staging systems of RECIST criteria and demands for a modification of radiologic response assessment with the consequence of a patient-tailored therapy in the clinical setting...
December 7, 2016: BMC Medicine
https://www.readbyqxmd.com/read/27918762/alternating-treatment-with-pazopanib-and-everolimus-vs-continuous-pazopanib-to-delay-disease-progression-in-patients-with-metastatic-clear-cell-renal-cell-cancer-the-ropetar-randomized-clinical-trial
#12
Geert A Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J L Loosveld, M Wouter Dercksen, Maartje Los, Marco B Polee, Franchette van den Berkmortel, Maureen J Aarts, Laurens V Beerepoot, Gerard Groenewegen, Martijn P Lolkema, Metin Tascilar, Johanna E A Portielje, Frank P J Peters, Heinz-Josef Klümpen, Vincent van der Noort, John B A G Haanen, Emile E Voest
Importance: To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective: To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib. Design, Setting, and Participants: This was an open-label, randomized (1:1) study (ROPETAR trial)...
December 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#13
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27842541/heterogeneous-response-and-progression-patterns-reveal-phenotypic-heterogeneity-of-tyrosine-kinase-inhibitor-response-in-metastatic-renal-cell-carcinoma
#14
Shanthini M Crusz, Yen Zhi Tang, Shah-Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltran, John Peters, Anju Sahdev, Axel Bex, Thomas Powles, Marco Gerlinger
BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the same patient. METHODS: We performed a retrospective central radiological analysis of patients with treatment-naïve metastatic ccRCC receiving anti-angiogenic tyrosine kinase inhibitors (TKIs) (sunitinib or pazopanib) within three similar phase II trials...
November 14, 2016: BMC Medicine
https://www.readbyqxmd.com/read/27823651/first-line-antiangiogenics-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#15
REVIEW
Benoît Rousseau, Emmanuelle Kempf, Gaelle Desamericq, Emilie Boissier, Marie Chaubet-Houdu, Charlotte Joly, Carolina Saldana, Helene Boussion, Cindy Neuzillet, Isabelle Macquin-Mavier, Stéphane Oudard, Laurent Salomon, Alexandre de la Taille, Christophe Tournigand
BACKGROUND: Sunitinib, pazopanib, sorafenib, axitinib and bevacizumab are the five recommended antiangiogenic agents in first-line therapy for metastatic renal cell carcinoma (mRCC). Because these drugs underwent simultaneous clinical development, no direct efficacy and safety comparison was ever conducted, thus preventing optimal therapy choices. METHODS: We performed a traditional and network meta-analysis to evaluate the efficacy and safety of mRCC-recommended first-line antiangiogenic agents...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27754995/prognostic-role-of-the-cumulative-toxicity-in-patients-affected-by-metastatic-renal-cells-carcinoma-and-treated-with-first-line-tyrosine-kinase-inhibitors
#16
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Ottavio de Cobelli, Franco Nolè
Tyrosine kinase inhibitor-related toxicities have been reported to be predictive and/or prognostic factors in patients affected by metastatic renal cell carcinoma (mRCC). We aim to investigate the incidence of cumulative toxicity and its prognostic role in mRCC patients treated with sunitinib or pazopanib. mRCC patients treated with sunitinib or pazopanib at the European Institute of Oncology in Milan were reviewed for the incidence of adverse events. Cumulative toxicity was defined as the presence of more than one selected adverse event of any grade...
February 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27721266/a-comparison-of-drug-resistances-of-targeted-drugs-for-advanced-renal-cell-cancer-approved-by-the-food-and-drug-administration-a-meta-analysis-of-randomized-clinical-trials
#17
Ming Guo, Yunsong Cao, Jingzhe Yang, Jingfeng Zhang
PURPOSE: The purpose of this study was to conduct network meta-analysis to assess drug resistances of the Food and Drug Administration-approved drugs for advanced renal cell carcinoma. MATERIALS AND METHODS: Database searches were conducted to identify randomized controlled trials reporting results for eligible treatments. After searching for PubMed, MEDLINE, EMBASE, and ISI Web of Science, 22 studies (n = 7854 patients) were included for the comparison of drug resistance in the present meta-analysis...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27721264/meta-analysis-of-therapeutic-effects-and-the-risks-of-hypertension-and-hyperglycemia-in-patients-with-renal-cell-carcinoma-who-were-receiving-antiangiogenic-drugs
#18
Lingling Chang, Ying An, Shuling Yang, Xiaosu Zhang
PURPOSE: A meta-analysis of published data was conducted to investigate the therapeutic effects in patients with renal cell carcinoma (RCC) who were receiving antiangiogenic drugs. METHODS: A computerized search through electronic databases, including PubMed (until February 2016), was performed to obtain eligible randomized controlled trials that compared the effectiveness of antiangiogenic with control groups (everolimus, placebo, and interferon [IFN] alfa) in patients with RCC...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27699042/simultaneous-occurrence-of-non-hodgkin-lymphoma-renal-cell-carcinoma-and-oncocytoma-a-case-report
#19
Ewa Zabrocka, Ewa Sierko, Stefan Jelski, Marek Z Wojtukiewicz
We herein report the case of a 74 year-old woman with a diffuse large B-cell lymphoma and bilateral renal masses identified on computed tomography scans during the initial staging process. Following partial bilateral nephrectomy, histopathological examination revealed renal cell carcinoma (RCC) and oncocytoma in the left and the right kidneys, respectively. Shortly afterwards, lymphoma of the left palatine tonsil was diagnosed and the patient received chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP regimen), followed by radiotherapy...
October 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27664394/improvement-in-survival-end-points-of-patients-with-metastatic-renal-cell-carcinoma-through-sequential-targeted-therapy
#20
REVIEW
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, Viktor Grünwald, Bernard Escudier
Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus, and the programmed death-1 (PD-1) targeted immune checkpoint inhibitor nivolumab...
November 2016: Cancer Treatment Reviews
keyword
keyword
113200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"